Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 2/20 | 0.44 |
| ▸ | MLX | Q9UH92 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 2/20 | 0.43 |
| ▸ | ELANE | P08246 | 8/20 | 0.42 |
| ▸ | CMA1 | P23946 | 1/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.38 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | REN | P00797 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30558184 | 0.91 | XIAP (0.43) | XIAPMLXACEELANECMA1 | |
| SCHEMBL29567397 | 0.90 | ELANE (0.50) | XIAPMLXACEELANECMA1 | |
| SCHEMBL29411300 | 0.88 | ELANE (0.46) | XIAPMLXACEELANECMA1 | |
| SCHEMBL29567142 | 0.87 | ELANE (0.42) | XIAPMLXELANECMA1 | |
| SCHEMBL1404290 | 0.87 | ACE (0.41) | XIAPMLXACEELANECMA1 | |
| SCHEMBL23229944 | 0.87 | ACE (0.41) | XIAPMLXACEELANECMA1 | |
| SCHEMBL1404295 | 0.87 | ACE (0.41) | XIAPMLXACEELANECMA1 | |
| SCHEMBL29566972 | 0.86 | XIAP (0.45) | XIAPMLXACEELANECMA1 | |
| SCHEMBL30263777 | 0.86 | REN (0.50) | ACEF2REN | |
| SCHEMBL30102197 | 0.86 | XIAP (0.41) | XIAPMLXACEELANECMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250186319-A1 | ANAPLEROTIC COMPOSITIONS AND USES THEREOF | EXCELLA BIOSCIENTIFIC LTD (IL) | 2025-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186319-A1 | ANAPLEROTIC COMPOSITIONS AND USES THEREOF | OAT, PC, ACAT1 | XIAP 3106/4885MLX 1278/4885ACE 2539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.